Vomiting News and Research RSS Feed - Vomiting News and Research

Vomiting is the process the body uses to eject some or all of the contents of the stomach through the mouth.
Ferring Pharmaceuticals to introduce new cranberry flavor option of PREPOPIK in 2015

Ferring Pharmaceuticals to introduce new cranberry flavor option of PREPOPIK in 2015

Colonoscopy is an important and widely used screening tool for colorectal cancer, but for many patients the bowel-preparation process is more uncomfortable than the procedure itself. To offer an alternative choice in bowel preparation, Ferring Pharmaceuticals Inc. will introduce a new cranberry flavor option of PREPOPIK in January 2015. [More]
Acacia Pharma reports positive results from APD421 Phase 3 studies for management of PONV

Acacia Pharma reports positive results from APD421 Phase 3 studies for management of PONV

Acacia Pharma announces positive Phase 3 results with APD421 for the management of post-operative nausea & vomiting (PONV). The data generated demonstrated a statistically significant reduction in the incidence of PONV with APD421 compared to placebo in adult surgical patients at moderate to high risk of suffering PONV (PONV is defined as any episode of emesis or use of antiemetic rescue medication in the first 24 hours after surgery). [More]
Correcting flaws in the Ebola response

Correcting flaws in the Ebola response

How hospital and health workers react to suspected cases of Ebola going forward is the subject of much scrutiny. But, even as public health and many elected officials urge calm, some potential 2016 presidential candidates say President Obama isn't doing enough to keep the disease out of the U.S. [More]
UPM researchers find way to enhance detection of rotavirus

UPM researchers find way to enhance detection of rotavirus

Researchers at the Universidad Politécnica de Madrid have found a way to enhance detection capacity of small concentrations of rotavirus. All this thanks to a new way to assess the biosensing response applied to an interferometric device. [More]
Family physician  answers questions related to Ebola virus

Family physician answers questions related to Ebola virus

According to the Centers for Disease Control, the outbreak of Ebola in four West African countries is one of the largest outbreaks of the disease in history. [More]
Rapid and coordinated response helps control Ebola outbreak in Nigeria

Rapid and coordinated response helps control Ebola outbreak in Nigeria

The Ebola outbreak in Nigeria appears to be nearing a possible end thanks to a rapid response coordinated by Nigeria's Emergency Operations Center with assistance from international partners, including the U.S. Centers for Disease Control and Prevention (CDC). [More]
Luminex gets FDA approval to add three new targets to xTAG Gastrointestinal Pathogen Panel

Luminex gets FDA approval to add three new targets to xTAG Gastrointestinal Pathogen Panel

Luminex Corporation today announced it has received U.S. FDA clearance to add three new targets to its xTAG Gastrointestinal Pathogen Panel (GPP). The targets include Adenovirus 40/41, Entamoeba histolytica and Vibrio cholerae. [More]
Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

A final analysis of the Phase 3 COU-AA-302 trial presented today at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain showed that ZYTIGA® (abiraterone acetate) plus prednisone significantly prolonged overall survival (OS), compared to an active control of placebo plus prednisone, in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC). [More]

Teva Canada recalls Biomedic Acetaminophen with Codeine owing to missing child-resistant packaging

Teva Canada Limited, in consultation with Health Canada, is recalling one lot (#669745) of Biomedic Acetaminophen with Codeine (30 caplets with 300 mg acetaminophen and 8 mg codeine) due to missing child-resistant packaging. [More]
Phase III trial: Rolapitant lessens chemotherapy-induced nausea and vomiting

Phase III trial: Rolapitant lessens chemotherapy-induced nausea and vomiting

Rolapitant reduces nausea and vomiting in patients receiving cisplatin-based chemotherapy, according to the results of a phase III trial presented for the first time today at the ESMO 2014 Congress in Madrid, Spain. [More]
Australian researchers use hookworms to reduce symptoms of celiac disease

Australian researchers use hookworms to reduce symptoms of celiac disease

Australian researchers have achieved groundbreaking results in a clinical trial using hookworms to reduce the symptoms of celiac disease. [More]
Understanding ways to treat, cure eosinophilic gastritis

Understanding ways to treat, cure eosinophilic gastritis

Investigators at Cincinnati Children's Hospital Medical Center have published the first study to extensively characterize eosinophilic gastritis (EG). [More]
People who experience migraine in middle age may develop movement disorders later in life

People who experience migraine in middle age may develop movement disorders later in life

A new study suggests that people who experience migraine in middle age may be more likely to develop Parkinson's disease, or other movement disorders later in life. Those who have migraine with aura may be at double the risk of developing Parkinson's, according to the study published in the September 17, 2014, online issue of Neurology, the medical journal of the American Academy of Neurology. [More]
RT alone effective in decreasing dysphagia in patients with advanced esophageal cancer

RT alone effective in decreasing dysphagia in patients with advanced esophageal cancer

Radiation therapy (RT) alone is as effective in decreasing swallowing complications experienced by advanced esophageal cancer patients as RT combined with chemotherapy, thus allowing patients to forgo chemotherapy, according to research presented today at the American Society for Radiation Oncology's 56th Annual Meeting. [More]
FDA approves Contrave extended-release tablets for chronic weight management

FDA approves Contrave extended-release tablets for chronic weight management

Takeda Pharmaceuticals U.S.A., Inc. and Orexigen® Therapeutics, Inc. jointly announced today that the U.S. Food and Drug Administration has approved Contrave® extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. [More]
Now, women experiencing morning sickness can benefit from Diclegis drug

Now, women experiencing morning sickness can benefit from Diclegis drug

Up to 85 percent of pregnant women are affected by nausea and vomiting of pregnancy (NVP), more commonly known as morning sickness. [More]
FDA approves Ferric Citrate for control of serum phosphorus levels in CKD patients on dialysis

FDA approves Ferric Citrate for control of serum phosphorus levels in CKD patients on dialysis

Keryx Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration approved Ferric Citrate (formerly known as Zerenex) for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. [More]
Drinking too much water and sports drinks may lead to death

Drinking too much water and sports drinks may lead to death

The recent deaths of two high school football players illustrate the dangers of drinking too much water and sports drinks, according to Loyola University Medical Center sports medicine physician Dr. James Winger. [More]
MEI Pharma completes patient enrollment in Pracinostat Phase II trial for treatment of MDS

MEI Pharma completes patient enrollment in Pracinostat Phase II trial for treatment of MDS

MEI Pharma, Inc., an oncology company focused on the clinical development of novel therapies for cancer, announced today that it has completed enrollment in a randomized Phase II clinical trial of its lead investigational drug candidate Pracinostat in combination with azacitidine in patients with previously untreated intermediate-2 or high-risk myelodysplastic syndrome (MDS). [More]
Researchers develop world's first app to measure tremor strength

Researchers develop world's first app to measure tremor strength

A 42-year-old investment banker arrives at the emergency department with complaints of nausea, vomiting, anxiety and tremor. [More]